Trial reportJournal of fluorescence2026
Testing the Use of Indocyanine Green Fluorescence Image-Guidance in Patients with Liver Surgery Compared To Patients with Standard Liver Surgery: A Feasibility Randomised Controlled Trial.
Trial report in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indocyanine-green Fluorescence-Image-Guidance (I-FIGS) is gaining popularity in liver surgery, yet its impact on reducing microscopic positive margins (R1-resection-rate) remains uncertain. The aim of this feasibility randomised-controlled-trial (fRCT) is to assess the logistics, recruitment, retention, and practicality of implementing I-FIGS in liver surgery to inform a full-scale multi-centre-RCT. Patients with liver tumours meeting the eligibility criteria were randomised to the control group (standard liver-surgery) or the I-FIGS group (standard liver-surgery + I-FIGS). Data were collected on demographics, screening, recruitment/retention rates, adherence to study methods, intraoperative details, and postoperative histology. Additionally, semi-structured-interviews were conducted with participants and analysed using thematic-analysis. From November 2022 -September 2023, 47 patients were screened, 42 recruited, and 29 analysed (control n = 15; I-FIGS n = 14). Overall adherence to study methods was 100%. The groups had comparable age and gender distribution. Compared to the control group, I-FIGS group had smaller median tumour size (34 vs. 20 mm), identical median blood loss (550 ml), shorter mean operating time (283.33 vs. 238.92 min), and reduced median hospital stay (7 vs. 4 days). Overall, 30-day-morbidity was lower in the I-FIGS group (40% vs. 7.4%). The R1 resection rate was comparable in both groups (25% vs. 28.6%). The fRCT demonstrated promising recruitment-rates and high adherence to study-methods. The results suggest potential benefits and improved patient-outcomes with I-FIGS. However, further research is required to study the role of I-FIGS in reducing R1 resection-rates. The qualitative findings provide valuable insights into participants’ experiences and can guide planning a multicentre-RCT.
Indexed as
Identifiers
41543661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.